EFFECTS OF CABERGOLINE TREATMENT ON METABOLIC SYNDROME AND VISCERAL ADIPOSITY INDEX IN PATIENTS WITH HYPERPROLACTINEMIA.

Risultato della ricerca: Other

Abstract

Introduction: Hyperprolactinemia is reportedly associated with an impaired metabolicprofile, particularly in patients with concomitant hypogonadism. The current study aimedat investigating the effects of short (12 months) and long (60 months) treatment withcabergoline (CAB) on metabolic complications, metabolic syndrome (MS) prevalence andvisceral adiposity index (VAI) in hyperprolactinemic patients (pts). Patients and Methods:Seventy-one pts (51 F, 20 M, aged 35.4±11.7 yrs), including 36 with microprolactinomas,32 with macroprolactinomas and 3 with non-tumoral hyperprolactinemia, entered thestudy. In all pts, PRL and metabolic parameters (BMI, waist circumference, lipid andglucose profile, insulin, VAI) were assessed at diagnosis and after 12 and 60 months ofcontinuous CAB treatment. MS was evaluated in line with NCEP-ATP III criteria. Results:Compared to baseline, CAB induced a significant decrease in PRL levels after 12 months(p=0.000) and a further decrease after 60 months (p=0.000) with complete normalization in93% of pts. At baseline, MS prevalence was significantly higher in pts with PRL above significantly decreased after 12 (12.6%, p= 0.009) and 60 (7%, p=0.000) months oftreatment compared to baseline (32.4%). Total cholesterol and triglycerides weresignificantly reduced after 12-month CAB compared to baseline (p=0.03), and furtherdecreased (p=0.000) after 60-month follow-up. HDL cholesterol resulted significantlyincreased after 60-month CAB compared to baseline (p=0.000) and 12 months (p=0.000).Glucose and insulin significantly decreased after 12 months of CAB (p=0.001), and werefurther improved after long-term CAB (p=0.03 and p=0.000 respectively) compared toshort-term therapy. Compared to baseline, a slight but not significant decrease in VAI wasfound at 12-month evaluation, whereas VAI was significantly decreased after 60 months oftreatment (p=0.000). Conclusions: Short-term CAB treatment significantly improvesmetabolic profile, so that to reduce MS prevalence, whereas longer treatment is required toachieve a significant improvement of VAI.
Lingua originaleEnglish
Numero di pagine1
Stato di pubblicazionePublished - 2013

Fingerprint Entra nei temi di ricerca di 'EFFECTS OF CABERGOLINE TREATMENT ON METABOLIC SYNDROME AND VISCERAL ADIPOSITY INDEX IN PATIENTS WITH HYPERPROLACTINEMIA.'. Insieme formano una fingerprint unica.

  • Cita questo